An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) will have its President and CEO, Todd C. Brady, M.D., Ph.D., participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference. The discussion, moderated by Marc Goodman from SVB Leerink, will be available on demand starting at 9:20 a.m. ET on February 16, 2022. Interested parties can access the webcast through the Investors & Media section of Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases with drug candidates like reproxalap and ADX-629 in clinical trials.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference.
Dr. Brady’s conversation with Marc Goodman, Senior Research Analyst at SVB Leerink, will be available on demand beginning at 9:20 a.m. ET Wednesday, February 16, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. The event will remain archived on the website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
Investor & Media:
Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Source: Aldeyra Therapeutics
FAQ
When will Aldeyra Therapeutics' CEO participate in the SVB Leerink Conference?
Todd C. Brady, M.D., Ph.D., CEO of Aldeyra Therapeutics, will participate in the SVB Leerink 2022 Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET.
How can I view the Aldeyra Therapeutics webcast?
The Aldeyra webcast can be viewed through the Investors & Media section of Aldeyra's website starting February 16, 2022, and will be available for 90 days.
What is Aldeyra Therapeutics known for?
Aldeyra Therapeutics is known for developing therapies for immune-mediated diseases, with key product candidates like reproxalap and ADX-629 in different phases of clinical trials.
What clinical trials are currently ongoing for Aldeyra's products?
Aldeyra's reproxalap is in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX-629 is in Phase 2 trials for psoriasis, asthma, and COVID-19.
